US11814429(CRESCENDO BIOLOGICS LTD [GB])
[0082] Thus, one aspect relates to the use of a single domain antibody as disclosed herein in a multivalent binding agent, for example in combination with a VH single domain antibody that blocks binding of PD-1 to its ligands PD-L1 and/or PD-L2. In one embodiment, this can be combined with a mAb or an Fc region of an antibody e.g. a Humabody® mAb fusion. This could enable longer half-life and or Fc effector function to deplete PD-1 positive cells for application in treating autoimmune diseases. In one embodiment, multivalent molecules find use as antagonists. In In one embodiment, multivalent molecules find use as agonists.
US2020378011(ENTEGRIS INC [US])
[0059] The disclosure in one aspect relates to a method of enhancing service life of a plasma source structure, component, or apparatus that in use or operation is exposed to plasma and voltage exceeding 1000 V, said method comprising coating plasma-wetted surface of said structure, component or apparatus with an ALD coating of alumina, and over coating said alumina coating with a PVD coating of aluminum oxynitride.
US11613741(NOVOZYMES AS [DK])
One aspect relates to the use of a polypeptide of the invention for reduction or removal of a biofilm from an item, such as textile, preferably is a cleaning process such as laundry.
US9253282(QUALCOMM INC [US])
[0012] Another aspect relates to a communications apparatus enabled to provide an improved user experience through use of an enriched user profile. The communications apparatus can include means for obtaining an attribute including a user specific informational element from a component operable on a communications device.
